Literature DB >> 29127156

MYC and tumor metabolism: chicken and egg.

Francesca R Dejure1, Martin Eilers2.   

Abstract

Transcription factors of the MYC family are deregulated in the majority of all human cancers. Oncogenic levels of MYC reprogram cellular metabolism, a hallmark of cancer development, to sustain the high rate of proliferation of cancer cells. Conversely, cells need to modulate MYC function according to the availability of nutrients, in order to avoid a metabolic collapse. Here, we review recent evidence that the multiple interactions of MYC with cell metabolism are mutual and review mechanisms that control MYC levels and function in response to metabolic stress situations. The main hypothesis we put forward is that regulation of MYC levels is an integral part of the adaptation of cells to nutrient deprivation. Since such mechanisms would be particularly relevant in tumor cells, we propose that-in contrast to growth factor-dependent controls-they are not disrupted during tumorigenesis and that maintaining flexibility of expression is integral to MYC's oncogenic function.
© 2017 The Authors.

Entities:  

Keywords:  zzm321990MYCzzm321990; zzm321990RNAPIIzzm321990; cancer; metabolic reprogramming; oncogene

Mesh:

Substances:

Year:  2017        PMID: 29127156      PMCID: PMC5709748          DOI: 10.15252/embj.201796438

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  127 in total

1.  c-Myc is crucial for the expression of LAT1 in MIA Paca-2 human pancreatic cancer cells.

Authors:  Keitaro Hayashi; Promsuk Jutabha; Hitoshi Endou; Naohiko Anzai
Journal:  Oncol Rep       Date:  2012-06-20       Impact factor: 3.906

2.  Downregulation of c-MYC protein levels contributes to cancer cell survival under dual deficiency of oxygen and glucose.

Authors:  Hiroaki Okuyama; Hiroko Endo; Tamaki Akashika; Kikuya Kato; Masahiro Inoue
Journal:  Cancer Res       Date:  2010-10-27       Impact factor: 12.701

Review 3.  PI3K and cancer: lessons, challenges and opportunities.

Authors:  David A Fruman; Christian Rommel
Journal:  Nat Rev Drug Discov       Date:  2014-02       Impact factor: 84.694

4.  Deregulated MYC expression induces dependence upon AMPK-related kinase 5.

Authors:  Lidan Liu; Jannes Ulbrich; Judith Müller; Torsten Wüstefeld; Lukas Aeberhard; Theresia R Kress; Nathiya Muthalagu; Lukas Rycak; Ramona Rudalska; Roland Moll; Stefan Kempa; Lars Zender; Martin Eilers; Daniel J Murphy
Journal:  Nature       Date:  2012-03-28       Impact factor: 49.962

5.  Akt and c-Myc differentially activate cellular metabolic programs and prime cells to bioenergetic inhibition.

Authors:  Yongjun Fan; Kathleen G Dickman; Wei-Xing Zong
Journal:  J Biol Chem       Date:  2009-12-17       Impact factor: 5.157

6.  ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation.

Authors:  Guoliang Qing; Bo Li; Annette Vu; Nicolas Skuli; Zandra E Walton; Xueyuan Liu; Patrick A Mayes; David R Wise; Craig B Thompson; John M Maris; Michael D Hogarty; M Celeste Simon
Journal:  Cancer Cell       Date:  2012-11-13       Impact factor: 31.743

Review 7.  The pentose phosphate pathway and cancer.

Authors:  Krushna C Patra; Nissim Hay
Journal:  Trends Biochem Sci       Date:  2014-07-15       Impact factor: 13.807

8.  Non-immunosuppressive triazole-based small molecule induces anticancer activity against human hormone-refractory prostate cancers: the role in inhibition of PI3K/AKT/mTOR and c-Myc signaling pathways.

Authors:  Wohn-Jenn Leu; Sharada Prasanna Swain; She-Hung Chan; Jui-Ling Hsu; Shih-Ping Liu; Mei-Ling Chan; Chia-Chun Yu; Lih-Ching Hsu; Yen-Lin Chou; Wei-Ling Chang; Duen-Ren Hou; Jih-Hwa Guh
Journal:  Oncotarget       Date:  2016-11-22

9.  Critical roles of Myc-ODC axis in the cellular transformation induced by myeloproliferative neoplasm-associated JAK2 V617F mutant.

Authors:  Megumi Funakoshi-Tago; Kazuya Sumi; Tadashi Kasahara; Kenji Tago
Journal:  PLoS One       Date:  2013-01-03       Impact factor: 3.240

10.  Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer.

Authors:  Roman Camarda; Alicia Y Zhou; Rebecca A Kohnz; Sanjeev Balakrishnan; Celine Mahieu; Brittany Anderton; Henok Eyob; Shingo Kajimura; Aaron Tward; Gregor Krings; Daniel K Nomura; Andrei Goga
Journal:  Nat Med       Date:  2016-03-07       Impact factor: 53.440

View more
  71 in total

1.  Tumor suppression by the EGR1, DMP1, ARF, p53, and PTEN Network.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Cancer Invest       Date:  2018-11-05       Impact factor: 2.176

2.  Role of Myc Proto-Oncogene as a Transcriptional Hub to Regulate the Expression of Regeneration-Associated Genes following Preconditioning Peripheral Nerve Injury.

Authors:  Hae Young Shin; Min Jung Kwon; Eun Mi Lee; Kyung Kim; Young Joo Oh; Hyung Soon Kim; Dong Hoon Hwang; Byung Gon Kim
Journal:  J Neurosci       Date:  2020-12-01       Impact factor: 6.167

3.  Homeodomain-interacting protein kinase 2 suppresses proliferation and aerobic glycolysis via ERK/cMyc axis in pancreatic cancer.

Authors:  Yi Qin; Qiangsheng Hu; Shunrong Ji; Jin Xu; Weixing Dai; Wensheng Liu; Wenyan Xu; Qiqing Sun; Zheng Zhang; Quanxing Ni; Xianjun Yu; Bo Zhang; Xiaowu Xu
Journal:  Cell Prolif       Date:  2019-04-01       Impact factor: 6.831

Review 4.  Polyamine synthesis as a target of MYC oncogenes.

Authors:  André S Bachmann; Dirk Geerts
Journal:  J Biol Chem       Date:  2018-11-07       Impact factor: 5.157

5.  Octamer transcription factor-1 induces the Warburg effect via up-regulation of hexokinase 2 in non-small cell lung cancer.

Authors:  Zhen Li; Jin Su; Mingming Sun; Jiaqi Song; Huanran Sun; Jun Fan; Guo Chen; Changliang Shan; Qi Qi; Shuai Zhang
Journal:  Mol Cell Biochem       Date:  2021-05-10       Impact factor: 3.396

Review 6.  MYC and tumor metabolism: chicken and egg.

Authors:  Francesca R Dejure; Martin Eilers
Journal:  EMBO J       Date:  2017-11-10       Impact factor: 11.598

Review 7.  Proteins moonlighting in tumor metabolism and epigenetics.

Authors:  Lei Lv; Qunying Lei
Journal:  Front Med       Date:  2021-01-02       Impact factor: 4.592

8.  AMPK promotes survival of c-Myc-positive melanoma cells by suppressing oxidative stress.

Authors:  Alain Kfoury; Marzia Armaro; Caterina Collodet; Jessica Sordet-Dessimoz; Maria Pilar Giner; Stefan Christen; Sofia Moco; Marion Leleu; Laurence de Leval; Ute Koch; Andreas Trumpp; Kei Sakamoto; Friedrich Beermann; Freddy Radtke
Journal:  EMBO J       Date:  2018-02-12       Impact factor: 11.598

9.  MRI Imaging of the Hemodynamic Vasculature of Neuroblastoma Predicts Response to Antiangiogenic Treatment.

Authors:  Konstantinos Zormpas-Petridis; Neil P Jerome; Matthew D Blackledge; Fernando Carceller; Evon Poon; Matthew Clarke; Ciara M McErlean; Giuseppe Barone; Alexander Koers; Sucheta J Vaidya; Lynley V Marshall; Andrew D J Pearson; Lucas Moreno; John Anderson; Neil Sebire; Kieran McHugh; Dow-Mu Koh; Yinyin Yuan; Louis Chesler; Simon P Robinson; Yann Jamin
Journal:  Cancer Res       Date:  2019-03-15       Impact factor: 12.701

10.  TAZ functions as a tumor suppressor in multiple myeloma by downregulating MYC.

Authors:  Stacy Grieve; Gabriel Wajnberg; Miranda Lees; Simi Chacko; Jackson Weir; Nicolas Crapoulet; Tony Reiman
Journal:  Blood Adv       Date:  2019-11-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.